Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.43 |
| ▸ | USP2 | O75604 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 7/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427031 | 0.87 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5423718 | 0.82 | TSHR (0.47) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5431852 | 0.81 | PKM (0.47) | TSHRALDH1A1SMN1; SMN2MEN1MAPK1 | |
| SCHEMBL5433821 | 0.81 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5418567 | 0.80 | HSD11B1 (0.53) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5419790 | 0.80 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5419655 | 0.80 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5430012 | 0.79 | CYP3A4 (0.54) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5425269 | 0.79 | CYP3A4 (0.42) | CYP3A4CYP1A2CYP2C9USP2TSHR | |
| SCHEMBL5425692 | 0.79 | LIPE (0.40) | CYP3A4CYP1A2CYP2C9USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | disclosed |
| EP-1683797-A1 | HETEROCYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | NR3C2, CBR1, CBR3 | CYP3A4 888/4885CYP1A2 909/4885CYP2C9 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.